Does gastric acid suppression affect sunitinib efficacy in patients with advanced or metastatic renal cell cancer?

Journal of Oncology Pharmacy Practice

Volumn 21, Issue 3, 2014, Pages 194-200

  Ha, Vincent H ^a,b   Ngo, Margaret ^b,c   Chu, Michael P ^a   Ghosh, Sunita ^a   Sawyer, Michael B ^a   Chambers, Carole R ^a  

^a CROSS CANCER INSTITUTE   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c TOM BAKER CANCER CENTRE   (Canada)

Author keywords

overall survival; progression free survival; proton pump inhibitors; renal cell cancer; Sunitinib

Indexed keywords

SUNITINIB; ANTACID AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; HUMAN; KIDNEY CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; STOMACH ACID; SURVIVAL TIME; TERTIARY CARE CENTER; TREATMENT DURATION; CARCINOMA, RENAL CELL; DISEASE FREE SURVIVAL; DRUG INTERACTION; KIDNEY NEOPLASMS; METABOLISM; MIDDLE AGED; PHYSIOLOGY; RETROSPECTIVE STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTACIDS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; DRUG INTERACTIONS; FEMALE; GASTRIC ACID; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PYRROLES; RETROSPECTIVE STUDIES;

EID: 84983123463     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155214527145     Document Type: Article

References (15)

1. Canadian Cancer Society, Toronto: Canadian Cancer Society, http://www.cancer.ca/en/cancer-information/cancer-type/kidney/statistics/?region=ab (2013, accessed 16 July 2013).
2. Budha NR, Frymoyer A, Smelick GS, et al. Drug absorption Interactions between oral targeted anticancer agents and PPIs: Is pH-dependent solubility the Achilles heel of targeted therapy?. Clin Pharmacol Ther. 2012 ; 92: 203-213
3. Medscape. Multi-drug interaction checker, http://reference.medscape.com/drug-interactionchecker (2013, accessed 1 August 2013).
4. Lexicomp. Lexicomp Online: Interactions, http://online. lexi.com/lco/action/interact (2013, accessed 1 August 2013).
5. Micromedex®. Drug Interactions search, http://www.micromedexsolutions.com/micromedex2/librarian (2013, accessed 1 August 2013).
6. Rock EP, Goodman V, Jiang JX, et al. Food and drug administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist. 2007 ; 12: 107-113
7. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009 ; 27: 3584-3590
8. Mullin JM, Gabello M, Murray LJ, et al. Proton pump inhibitors: actions and reactions. Drug Discov Today. 2009 ; 14: 647-660
9. Yang YX, Metz DC. Safety of proton pump inhibitor exposure. Gastroenterology. 2010 ; 139: 1115-1127
10. Lexicomp. Sunitinib Malate, http://online.lexi.com/lco/action/doc/retrieve/docid/patch-f/371693 (2013, accessed 1 August 2013).
11. Chu MP, Ghosh S, Chambers C, et al. Acid suppression therapy impairs erlotinib efficacy in non-small cell lung cancer. In: World conference on lung cancer, Sydney, New South Wales, Australia, 27-30 October 2013, abstract #2930.
12. Eley T, Luo FR, Agrawal S, et al. Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects. J Clin Pharmacol. 2009 ; 49: 700-709
13. Di Gion P, Kanefendt F, Lindauer A, et al. Clinical pharmacokinetics of tyrosine kinase inhibitors. Clin Pharmacokinet. 2011 ; 50: 551-603
14. Kirchheiner J, Glatt S, Fuhr U, et al. Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. Eur J Clin Pharmacol. 2009 ; 65: 19-31
15. Shin JM, ad Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 2013 ; 19: 25-35